Which GLP-1 causes the least nausea?

Nausea is common to all of them and is driven more by how fast the dose goes up than by which drug it is. Broadly, the drugs producing the largest weight loss also produce the most gastrointestinal symptoms, and every one of them is worst around a dose increase and settles afterwards.

Is retatrutide approved?

No. At the time of review it was not approved by any regulator anywhere, and was still in phase 3 trials, despite being sold widely as a research peptide. An unlicensed vial carries no guarantee of purity, dose accuracy or sterility, and no clinician is watching what it does to you.

Does the tablet form change how I should eat?

Oral semaglutide does: it has to be taken on an empty stomach with a small sip of water, with nothing else for at least 30 minutes afterwards, or absorption drops sharply. Orforglipron, the newer non-peptide tablet, has no such food or water restriction.

Does a stronger drug mean I need to eat differently?

Not differently, but more deliberately. The bigger the weight loss, the more lean tissue is in play and the smaller the margin for under-eating protein, so the protein target and the resistance training matter more, not less.

GLP-1 Medications Compared: What Each One Means for Eating

Every drug people ask about, with its status stated plainly and its practical eating implications.

Read this first: food advice, not medical advice

These are prescription medicines. Everything here is about what and how to eat while you are on one; nothing here is dosing, titration or prescribing guidance, and none of it replaces your prescriber, GP or dietitian.
Persistent vomiting, an inability to keep fluids down, or severe stomach pain that spreads to your back and does not go away are reasons to seek medical help the same day, not to adjust your diet and hope.
If you also take insulin or a sulfonylurea, eating much less can drop your blood sugar too low. Your prescriber needs to know before you cut your intake.
Buying these compounds outside a pharmacy, including anything sold as a research peptide, means no guarantee of purity, dose accuracy or sterility, and no clinician watching what happens next.
If you are pregnant, trying to conceive or breastfeeding, or have a history of pancreatitis, gallbladder disease or an eating disorder, talk to your clinician before changing how you eat on these drugs.

Why a nutrition page cares which drug it is

For the most part it does not. Every drug on this page works through the same two levers, appetite and stomach emptying, so the eating advice is the same: protein first, small and often, fat down, fibre and fluid on purpose.

Three things do differ, and each changes something practical:

How it is taken. A weekly injection concentrates side effects into the days after the dose. A daily drug spreads them. Oral semaglutide, uniquely, dictates your first half-hour of the day.
How much weight comes off. Bigger losses mean more lean tissue in play, which raises the stakes on protein and resistance training rather than changing the principles.
Whether it is a licensed medicine at all. Two of the entries below are not approved anywhere, and one of those is being bought and used anyway. One more has been discontinued in the UK entirely, which matters mainly because everyone on it has been switched to something considerably stronger.

A note on status, since it moves fast

The status column reflects the position at the review date at the foot of this page. This field changes every few months: new approvals, new strengths, new routes. Check with your prescriber or the current MHRA and NHS guidance rather than trusting any web page, including this one, to be current on the day you read it.

The one that is different in kind

Semaglutide, tirzepatide, liraglutide and dulaglutide are licensed medicines with published trial programmes and a clinician between you and the vial. Retatrutide is not. It is a genuinely impressive drug in trials, still in phase 3, approved by nobody, and sold widely as a "research peptide" to people who inject it without supervision. An unlicensed vial has no guarantee of purity, dose accuracy or sterility, which is a different category of risk from a side effect, and no nutrition plan compensates for it. The same reasoning applies across our peptides reference.

Each one, and what it means for eating

The table below is the at-a-glance version; the sections beneath it give the detail for each drug, including what the trials found, how appetite and digestion typically behave, and the practical eating implications.

Medicine	What it acts on	How it is taken	Status
SemaglutideWegovy, Ozempic, Rybelsus	GLP-1 receptor agonist	Weekly injection, or a daily tablet	Licensed in the UK
TirzepatideMounjaro, Zepbound	Dual GIP and GLP-1 receptor agonist	Weekly injection	Licensed in the UK
LiraglutideSaxenda, Victoza	GLP-1 receptor agonist	Daily injection	Licensed in the UK
DulaglutideTrulicity	GLP-1 receptor agonist	Weekly injection	Licensed in the UK
ExenatideByetta, Bydureon	GLP-1 receptor agonist (the original one)	Twice-daily or weekly injection	Discontinued in the UK
OrforglipronFoundayo	Non-peptide GLP-1 receptor agonist (a small molecule, not an injectable peptide)	Daily tablet	Licensed elsewhere, not yet routine in the UK
Cagrilintide with semaglutide (CagriSema)	Amylin analogue combined with a GLP-1 receptor agonist	Weekly injection	Not approved anywhere
Retatrutide	Triple GIP, GLP-1 and glucagon receptor agonist	Weekly injection	Not approved anywhere

Semaglutide

Wegovy, Ozempic, Rybelsus

Licensed in the UK

What it acts on: GLP-1 receptor agonist
How it is taken: Weekly injection, or a daily tablet
Where it stands: Licensed in the UK for weight management (Wegovy) and type 2 diabetes (Ozempic, Rybelsus). A higher-strength injection and an oral 25 mg weight-management tablet were both cleared by the MHRA during 2026.
What the trials found: About 15% average body-weight reduction at 68 weeks on the 2.4 mg injection in STEP 1, against 2.4% on placebo.
Appetite and digestion: The reference profile everything else gets compared with: strong appetite suppression, marked early fullness, and gastrointestinal effects in roughly three-quarters of people, overwhelmingly mild to moderate and concentrated around dose increases.

What it means for how you eat

Because the injection is weekly, side effects often follow a rhythm: the day or two after the dose is when small, low-fat meals matter most.
The oral form is the exception to almost every rule here. It has to be swallowed on an empty stomach with a small sip of water, with nothing else to eat or drink for at least 30 minutes, or you absorb far less of it. That makes the first half-hour of the day a fixed appointment.
Protein first at every meal, because a full week of appetite suppression is a full week of under-eating protein if you leave it to chance.

Tirzepatide

Mounjaro, Zepbound

Licensed in the UK

What it acts on: Dual GIP and GLP-1 receptor agonist
How it is taken: Weekly injection
Where it stands: Licensed in the UK for weight management and type 2 diabetes, and the most-prescribed option here as NHS access widened through 2026.
What the trials found: Up to about 21% average body-weight reduction at 72 weeks on the 15 mg dose in SURMOUNT-1.
Appetite and digestion: Similar in kind to semaglutide but generally stronger in effect on weight; the added GIP action is thought to temper nausea somewhat, though gastrointestinal symptoms are still the most common complaint and still cluster around dose increases.

What it means for how you eat

Larger and faster weight loss raises the stakes on protein and resistance training, not lowers them.
Appetite suppression can be profound enough that people forget to eat entirely. A scheduled protein-led breakfast is the cheapest insurance there is.
In the SURMOUNT-1 body-composition substudy about 74% of the weight lost was fat and 26% lean, essentially the same split as placebo, so the muscle question is about the size of the loss rather than the drug being unusually unkind to muscle.

Liraglutide

Saxenda, Victoza

Licensed in the UK

What it acts on: GLP-1 receptor agonist
How it is taken: Daily injection
Where it stands: Licensed in the UK for weight management (Saxenda) and type 2 diabetes (Victoza); the older, shorter-acting option, now also available as a generic.
What the trials found: Typically around 5 to 10% average body-weight reduction, less than the weekly drugs.
Appetite and digestion: Shorter-acting, so appetite suppression is flatter across the day but fades faster if a dose is missed. Its effect on stomach emptying is the best studied, and in many people it wanes over the first few months rather than persisting.

What it means for how you eat

Daily dosing means fewer peaks and troughs than a weekly injection, so eating patterns tend to be steadier week to week.
If the early fullness eases after a few months, that is expected physiology, not the drug failing. Keep the protein-first habit anyway.
Missing doses reintroduces appetite quickly, which is worth planning meals around rather than being caught out by.

Dulaglutide

Trulicity

Licensed in the UK

What it acts on: GLP-1 receptor agonist
How it is taken: Weekly injection
Where it stands: Licensed in the UK for type 2 diabetes only, not for weight management. Widely prescribed, so plenty of people are on a GLP-1 without ever having been given weight-loss dietary advice with it.
What the trials found: Weight change is modest, typically a few kilograms across the AWARD trial programme, because it is dosed for blood-sugar control rather than weight.
Appetite and digestion: The same family of effects at a gentler intensity: nausea, reduced appetite and some gut upset, usually worst in the first days and easing over a couple of weeks.

What it means for how you eat

Because it is prescribed for diabetes, meal regularity matters more here than on the weight-management drugs, particularly if you also take insulin or a sulfonylurea.
Milder appetite suppression means less risk of under-eating protein, but the protein-first habit still costs nothing.
Carbohydrate timing and blood-sugar targets come from your diabetes team, not from a food page.

Diabetes UK. Trulicity (dulaglutide): uses, how it works and side effects

Exenatide

Byetta, Bydureon

Discontinued in the UK

What it acts on: GLP-1 receptor agonist (the original one)
How it is taken: Twice-daily or weekly injection
Where it stands: Discontinued in the UK: Byetta went in March 2024 and Bydureon supplies were exhausted after an October 2025 supply notification. It is here because people still search for it and because anyone moved off it has been switched to one of the drugs above.
What the trials found: Smaller weight effects than any current option, which is part of why it was superseded.
Appetite and digestion: Shorter-acting than everything else here, with nausea concentrated around each injection rather than spread across a week.

What it means for how you eat

If you have been switched from exenatide to semaglutide or tirzepatide, expect a considerably stronger appetite effect and plan protein accordingly rather than assuming your old eating pattern transfers.
A switch between drugs restarts the escalation-linked side effects, so the small-meals, low-fat approach is worth reinstating for the first few weeks.

Diabetes UK. Exenatide: uses, how it works and side effects

Orforglipron

Foundayo

Licensed elsewhere, not yet routine in the UK

What it acts on: Non-peptide GLP-1 receptor agonist (a small molecule, not an injectable peptide)
How it is taken: Daily tablet
Where it stands: Approved in the United States in April 2026 for chronic weight management. UK licensing and NHS availability were still catching up at the time of review, so treat availability here as a question for your prescriber.
What the trials found: About 12% average body-weight reduction at the highest dose in its phase 3 programme, less than the weekly injections.
Appetite and digestion: The same family of appetite and digestion effects as the injectables, at a generally smaller magnitude in line with its smaller weight effect.

What it means for how you eat

Unlike oral semaglutide, it does not require an empty stomach or a food-and-water gap, which removes the most disruptive scheduling constraint of the tablet route.
Smaller average weight loss means a smaller lean-mass loss to defend against, but the protein and training principles are unchanged.

Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr 2025

Cagrilintide with semaglutide (CagriSema)

Not approved anywhere

What it acts on: Amylin analogue combined with a GLP-1 receptor agonist
How it is taken: Weekly injection
Where it stands: Filed with the US regulator in December 2025, with a decision expected around late 2026. Not licensed in the UK at the time of review.
What the trials found: About 20% average body-weight reduction at 68 weeks in REDEFINE 1; a head-to-head trial against tirzepatide did not show it to be better.
Appetite and digestion: Adds amylin signalling, which independently slows gastric emptying and increases fullness, on top of the GLP-1 effect. Early fullness and nausea are correspondingly prominent.

What it means for how you eat

Two fullness mechanisms stacked together makes the small-meals, protein-first, fluid-between-meals approach more important, not less.
Nothing about a combination product changes the rule that eating too much fat in one sitting is the reliable way to feel unwell.

Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr 2025

Retatrutide

Not approved anywhere

What it acts on: Triple GIP, GLP-1 and glucagon receptor agonist
How it is taken: Weekly injection
Where it stands: Not approved by any regulator anywhere at the time of review; still in phase 3, with a first regulatory submission expected no earlier than late 2026. It is nonetheless sold widely as a grey-market research peptide, which is a genuinely different risk from anything else on this page: unverified purity, unverified dose, no sterility guarantee and no clinician involved.
What the trials found: About 25% average body-weight reduction at 80 weeks on the 12 mg dose in the phase 3 TRIUMPH-1 trial, against 3.9% on placebo, with up to roughly 30% reported at the top of the programme.
Appetite and digestion: The strongest appetite suppression of the group, and gastrointestinal side effects to match: nausea was reported by up to around 60% of people at the highest dose in phase 2, again worst during dose escalation.

What it means for how you eat

At this scale of weight loss the muscle question stops being theoretical. Protein at the top of the range and genuine resistance training are the difference between losing fat and losing your physique.
Under-eating is the practical risk rather than over-eating. Liquid protein, small frequent meals and a fixed eating schedule are what keep intake adequate.
Micronutrients matter when total intake is very low for months; this is worth an actual conversation with a dietitian.
None of this is an endorsement of buying it. An unlicensed vial has no quality guarantee, and nothing in a nutrition plan compensates for that.

Sources

Work out your numbers

Frequently asked questions

Which GLP-1 causes the least nausea?: Nausea is common to all of them and is driven more by how fast the dose goes up than by which drug it is. Broadly, the drugs producing the largest weight loss also produce the most gastrointestinal symptoms, and every one of them is worst around a dose increase and settles afterwards.
Is retatrutide approved?: No. At the time of review it was not approved by any regulator anywhere, and was still in phase 3 trials, despite being sold widely as a research peptide. An unlicensed vial carries no guarantee of purity, dose accuracy or sterility, and no clinician is watching what it does to you.
Does the tablet form change how I should eat?: Oral semaglutide does: it has to be taken on an empty stomach with a small sip of water, with nothing else for at least 30 minutes afterwards, or absorption drops sharply. Orforglipron, the newer non-peptide tablet, has no such food or water restriction.
Does a stronger drug mean I need to eat differently?: Not differently, but more deliberately. The bigger the weight loss, the more lean tissue is in play and the smaller the margin for under-eating protein, so the protein target and the resistance training matter more, not less.

Written and reviewed by Mathew Beale, MSc Biotechnology, University of Reading.

Last reviewed: 29 July 2026

GLP-1 Medications Compared: What Each One Means for Eating

Why a nutrition page cares which drug it is

A note on status, since it moves fast

The one that is different in kind

Each one, and what it means for eating

Semaglutide

Tirzepatide

Liraglutide

Dulaglutide

Exenatide

Orforglipron

Cagrilintide with semaglutide (CagriSema)

Retatrutide

Sources

Work out your numbers

Frequently asked questions

Related